Omaglip
Generic Name
Omagliptin
Manufacturer
Medix Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| omaglip 125 mg tablet | ৳ 80.00 | ৳ 320.00 |
Description
Overview of the medicine
Omaglip 125 mg Tablet contains Omagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, used for the management of type 2 diabetes mellitus. It helps to improve glycemic control by enhancing the body's natural ability to lower blood glucose levels.
Uses & Indications
Dosage
Adults
The recommended dose is 125 mg once daily, taken orally with or without food.
Elderly
No dose adjustment is generally required based on age alone, but renal function should be assessed.
Renal_impairment
For patients with moderate to severe renal impairment (CrCl < 50 mL/min) or end-stage renal disease requiring dialysis, the dose should be reduced to 62.5 mg once daily. Close monitoring is recommended.
How to Take
Omaglip 125 mg Tablet should be taken orally once daily, with or without food. Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.
Mechanism of Action
Omagliptin is a highly selective and potent inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, Omagliptin increases the levels of active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretins enhance glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon secretion from pancreatic alpha cells, leading to improved glycemic control.
Pharmacokinetics
Onset
Within 1-2 hours
Excretion
Mainly renal excretion of unchanged drug or metabolites.
Half life
Approximately 12-24 hours (variable depending on specific gliptin)
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations reached within 1-4 hours. Bioavailability is high (e.g., >80%).
Metabolism
Primarily hepatic, often involving CYP enzymes (e.g., CYP3A4, CYP2C8) for some gliptins, but many have minimal hepatic metabolism.
Side Effects
Contraindications
- Hypersensitivity to Omagliptin or any component of the tablet.
- History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) to any DPP-4 inhibitor.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
Drug Interactions
Digoxin
May increase digoxin plasma concentrations; monitor digoxin levels if co-administered.
Cyclosporine
Some gliptins may have altered pharmacokinetics when co-administered with strong CYP3A4 inhibitors (like cyclosporine), though this is less common for some.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, it is reasonable to employ standard supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient’s clinical status). Omagliptin is unlikely to be removed by hemodialysis.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm, but adequate and well-controlled studies in pregnant women are lacking. Use during pregnancy only if clearly needed. It is unknown whether Omagliptin is excreted in human milk; caution should be exercised when administered to a nursing mother.
Side Effects
Contraindications
- Hypersensitivity to Omagliptin or any component of the tablet.
- History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) to any DPP-4 inhibitor.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
Drug Interactions
Digoxin
May increase digoxin plasma concentrations; monitor digoxin levels if co-administered.
Cyclosporine
Some gliptins may have altered pharmacokinetics when co-administered with strong CYP3A4 inhibitors (like cyclosporine), though this is less common for some.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, it is reasonable to employ standard supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient’s clinical status). Omagliptin is unlikely to be removed by hemodialysis.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm, but adequate and well-controlled studies in pregnant women are lacking. Use during pregnancy only if clearly needed. It is unknown whether Omagliptin is excreted in human milk; caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved (Hypothetical)
Patent Status
Patent Pending
Clinical Trials
Ongoing phase III clinical trials are assessing Omagliptin's efficacy and safety in various patient populations and in combination therapies. Early phase trials showed promising results in glycemic control.
Lab Monitoring
- HbA1c levels (every 3-6 months)
- Fasting plasma glucose
- Renal function (e.g., eGFR, creatinine) periodically
Doctor Notes
- Emphasize patient education on hypoglycemia symptoms, especially when prescribed with sulfonylureas or insulin.
- Advise patients to report severe, persistent abdominal pain promptly due to the risk of pancreatitis.
- Monitor renal function regularly in elderly and renally impaired patients.
Patient Guidelines
- Take Omaglip 125 mg Tablet exactly as prescribed by your doctor.
- Do not stop taking this medication without consulting your doctor.
- Report any unusual symptoms or severe side effects, especially persistent severe abdominal pain (possible pancreatitis) or severe joint pain.
Missed Dose Advice
If a dose of Omaglip is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Omaglip 125 mg Tablet is not known to affect the ability to drive or operate machinery. However, if you experience symptoms like dizziness or blurred vision, which could be associated with hypoglycemia (especially in combination therapy), avoid driving or operating machinery.
Lifestyle Advice
- Maintain a healthy diet and regular exercise routine.
- Monitor blood glucose levels regularly as advised by your doctor.
- Avoid excessive alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Omaglip Brand
Other medicines available under the same brand name
